CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and ...

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.

Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

From groundbreaking immunotherapies to advanced targeted treatments, oncology is set to make historic strides in the year ...

NICE rejected Opdivo (nivolumab) in this use in a preliminary decision in April because of uncertainties in the clinical evidence, before the drug had even received its European licence.

Opdivo (nivolumab) is the frontrunner in the PD-1 class of checkpoint inhibitor drugs, a new generation of immunotherapy drugs expected to advance treatment across many different tumour types ...

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...